2026 Cholesterol Guidelines Reveal Massive Treatment Gaps: 1 in 3 Americans Miss LDL Goals, 21.5 Million Newly Eligible for Statins
核心洞察
Nearly 1 in 3 U.S. adults without heart disease have LDL cholesterol (搜索) above the new 2026 ACC/AHA guideline goals, and about 76% of them are not receiving any cholesterol-lowering medication.
Among adults with established cardiovascular disease, nearly 4 in 5 are above the recommended LDL targets, with 38% receiving no treatment at all.
The 2026 guideline expands primary prevention statin eligibility to an additional 21.5 million Americans, bringing the total to 87.5 million (56.6% of adults aged 30–79).
A pair of studies published in JAMA reveal that the newly released 2026 ACC/AHA dyslipidemia (搜索) guidelines expose stark gaps between recommended LDL cholesterol (搜索) targets and actual levels in the U.S. population, while simultaneously expanding statin eligibility to millions more Americans.
A Mass General Brigham (搜索) analysis of NHANES 2021–2023 data, representing approximately 178 million U.S. adults aged 30 to 79, found that about one-third of adults without a history of heart attack, stroke, or other cardiovascular events had LDL levels above the new recommended goals. Among those above target, roughly 76% were not receiving any cholesterol-lowering medication.
"The gap between where the country's cholesterol levels actually are and where the new guidelines say they should be is much wider than most people realize," said lead author Shady Abohashem, MD, MPH, Head of Cardiac PET/CT Imaging Trials in the Cardiovascular Imaging Research Center with Mass General Brigham (搜索) Heart and Vascular Institute. "Heart disease remains a leading cause of death in this country, and a large share of heart attacks and strokes are preventable with medications we've had for decades. Yet many people who could benefit from treatment aren't getting any. That is a missed opportunity at the scale of millions."
Two Distinct Problems, Two Different Solutions
The analysis, which examined approximately 2,300 adults, found that the treatment gap manifests differently depending on whether patients are in the primary or secondary prevention group.
Among those at the highest cardiovascular risk without established disease, about 83% were above goal, and roughly half were not receiving any cholesterol-lowering medication. For adults with established heart disease—the secondary prevention group—nearly 4 of 5 were above the recommended goal. However, most of these patients (roughly 62%) were already receiving cholesterol-lowering therapy but failing to reach the lower targets, indicating a need for treatment intensification rather than initiation. The remaining 38% were receiving no treatment at all.
"The good news is we know exactly what works, and the evidence behind these therapies is among the strongest in medicine," Abohashem said. "But these are really two different problems requiring two different solutions. In people without heart disease, most who are above target aren't on any cholesterol-lowering medication at all, so the first step is simply starting treatment. Whereas in people who have already had a heart attack or stroke, most are already on a statin but still aren't reaching the goal. For them, the answer isn't starting therapy; it's intensifying it."
The 2026 guideline introduced a new cardiovascular risk calculator—the PREVENT-ASCVD equations—and lowered LDL treatment goals, reflecting evidence that increasingly supports a "lower is better" approach for higher-risk patients. Under the updated framework, recommended LDL levels vary by cardiovascular risk: for low-risk adults, treatment consideration begins at 160 mg/dL or higher, while for those with established heart disease and very high risk of future events, the target is below 55 mg/dL.
Statin Eligibility Expands by 21.5 Million
A separate study led by the University of Pittsburgh and the VA Pittsburgh Healthcare System quantified how the 2026 guideline altered the U.S. population eligible for primary prevention statin therapy. Analyzing NHANES data from 2017 to 2023 representing 154.5 million U.S. adults, researchers estimated that the new guideline expands statin eligibility to 21.5 million adults not previously recommended for therapy.
In total, an estimated 87.5 million U.S. adults—56.6% of the target population—are now eligible for statins (搜索) under the 2026 guideline. This includes more than 93% of adults aged 70 to 79 years and 85% of adults aged 60 to 69 years, compared with just 11% of adults aged 30 to 39 years.
"Newly statin-eligible populations were largely younger and lower risk than populations previously recommended statin therapy," the authors noted, with a mean estimated 10-year ASCVD risk of 3.1% for newly eligible individuals versus 6.1% for those previously eligible.
Five Key Guideline Changes Driving Expansion
The researchers identified five major changes in the 2026 guideline that impact statin eligibility. The population target for ASCVD risk estimation was expanded from ages 40–75 to ages 30–79. The guideline added stage 3 or higher chronic kidney disease and HIV infection as statin-eligible indications independent of risk estimation. ASCVD risk category thresholds were lowered, with low risk now defined as less than 3.0%. The strength of recommendation for statin initiation in borderline-risk individuals was increased from weak to moderate, and a new moderate recommendation was added for patients with low 10-year risk and either LDL-C of 160–189 mg/dL or 30-year ASCVD risk of 10% or greater. Finally, the PREVENT-ASCVD equations replaced the pooled cohort equations for 10-year risk estimation.
The adoption of PREVENT equations, which produce nearly 50% lower 10-year risk estimates than the prior PCEs, might seem paradoxical given the expansion in eligibility. The authors explained: "This is a result of the 2026 guideline lowering thresholds for risk categories and recommending statins (搜索) for new reasons other than 10-year risk."
A Baseline for Future Progress
The Mass General Brigham (搜索) data were collected before the 2026 guidelines were published, establishing a baseline to track progress as the new recommendations are adopted in practice. Falling short of LDL treatment goals is a persistent, long-standing problem with multiple contributing factors including limited access to newer medications, gaps in patient awareness, and structural barriers within the health system.
"What we're measuring here is a starting line, not a verdict," Abohashem stated. "The new guidelines give us a clearer goal than we've ever had. For clinicians, that means reevaluating patients against the updated targets. And for the public, the message is simpler: know your LDL number, know your personal target, and if you don't know either, ask your doctor."